Commerzbank: Preliminary CET 1 ratio per end of June 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Commerzbank: Preliminary CET 1 ratio per end of June 2016 at 11.5% - group net profit for the second quarter 2016 in line with consensus

25.07.2016 21:37

Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

----------------------------

On the basis of preliminary figures Commerzbank posted an Operating profit of EUR342 million (Q2 2015: EUR419 million). Net profit attributable to Commerzbank shareholders stood at EUR209 million in the second quarter 2016 (Q2 2015: EUR307 million). Both are in line with consensus.

The Common Equity Tier 1 ratio (CET 1) under full application of Basel 3 stood at 11.5% at the end of June 2016 (end of March 2016: 12.0%; end of June 2015: 10.5%) based on preliminary figures. This ratio includes a dividend accrual of 10 cents per share for the first half of 2016.

The change in the CET1 ratio mainly results from the following non-operating valuation and methodology effects:

  - Higher risk-weighted assets (RWA) in particular for operational risks due to the consideration of new external events factored in by external databases representing industrywide damage claims of banks.

  - Higher pension liabilities due to lower discount factors (reduced from 2% to 1.7%) as well as higher capital deductions from revaluation reserves in particular driven by higher credit spreads for Italian sovereign debt.

As already stated in the past, the capital ratio can be volatile in the current market environment. Commerzbank's ambition remains to keep its capital ratio under full application of Basel 3 above SREP-requirements.

Figures shown in this release are preliminary. Commerzbank will publish its final figures for the second quarter 2016 on 2 August 2016.

****

Disclaimer

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. In this release, these statements concern inter alia the expected future business of Commerzbank, efficiency gains and expected synergies, expected growth prospects and other opportunities for an increase in value of Commerzbank as well as expected future financial results, restructuring costs and other financial developments and information. These forward-looking statements are based on the management's current plans, expectations, estimates and projections. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from any future results and developments expressed or implied by such forward-looking statements. Such factors include the conditions in the financial markets in Germany, in Europe, in the USA and other regions from which Commerzbank derives a substantial portion of its revenues and in which Commerzbank holds a substantial portion of its assets, the development of asset prices and market volatility, especially due to the ongoing European debt crisis, potential defaults of borrowers or trading counterparties, the implementation of its strategic initiatives to improve its business model, particularly to reduce its ACR portfolio, the reliability of its risk management policies, procedures and methods, risks arising as a result of regulatory change and other risks. Forward-looking statements therefore speak only as of the date they are made. Commerzbank has no obligation to update or release any revisions to the forward-looking statements contained in this release to reflect events or circumstances after the date of this release.

Contact:

Commerzbank AG

Group Communications

Tel.: +49 69 136 - 22830

mediarelations@commerzbank.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 241

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 361

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 280

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 102

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 70

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 256

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 158

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 127

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading

Top 5 Most Recently Viewed Articles

What Your $1000 Investment in ASML Could Be Worth Now

Updated Category News Views 269

Exploring ASML Holding's Remarkable Growth ASML Holding (NASDAQ: ASML) has established itself as a leader in the semiconductor industry, offering substantial growth for investors. Over the past 15 years, the stock has consistently outperformed the market, delivering an impressive annualized return of 23.78%. This performance exceeds the overall market's growth by 11.35%,...

Continue Reading
Nvidia and Adobe Lead Stock Movement Trends This Week

Updated Category News Views 87

Significant Stock Movements in Today's Market Today's trading session has brought notable activity in the stock market, particularly among mega-cap and large-cap companies. With significant price fluctuations and market activity, investors are closely analyzing trends influenced by various factors, such as earnings reports and market sentiment. Mega-Cap Market Movers When...

Continue Reading
Charlotte's Web Unveils Innovative Quiet Sleep Mushroom Gummies

Updated Category News Views 184

Charlotte's Web Launches Quiet Sleep Mushroom Gummies A recent survey highlights that 43% of Americans struggle with sleep due to racing thoughts. To address this common issue, Charlotte's Web Holdings, Inc. introduces a natural remedy in the form of Quiet Sleep Mushroom Gummies. These gummies are melatonin-free and free from CBD, utilizing the calming properties of...

Continue Reading
Brown Brothers Harriman Expands Team with New Senior Wealth Planner

Updated Category News Views 258

Brown Brothers Harriman Enhances Wealth Planning Services Brown Brothers Harriman & Co. (BBH) has taken a significant step in strengthening its Chicago presence by welcoming Kristina White as a Senior Wealth Planner. With years of experience as a Managing Director and Partner at McDermott Will & Emery, Kristina brings a wealth of expertise in sophisticated wealth...

Continue Reading
Hospitality Sector Innovates to Overcome Market Challenges

Updated Category News Views 78

Hospitality Sector Innovates to Tackle Market Challenges In recent years, hospitality stocks have contended with major obstacles, including economic uncertainties and shifts in global markets. Despite these challenges, this industry has shown remarkable resilience, continually adapting and innovating to thrive amid adversity. As Wall Street watches for economic changes,...

Continue Reading